Terms: = Liver cancer AND LASP1, ENSG00000002834, 3927, Q14847, MLN50, Lasp-1 AND Treatment
9 results:
1. Long noncoding RNA PPP1R14B-AS1 imitates microRNA-134-3p to facilitate breast cancer progression by upregulating LIM and SH3 protein 1.
Zhou L; Zhang L; Guan X; Dong YI; Liu T
Oncol Res; 2021; 29(4):251-262. PubMed ID: 37303940
[TBL] [Abstract] [Full Text] [Related]
2. TRIM15 forms a regulatory loop with the AKT/FOXO1 axis and lasp1 to modulate the sensitivity of HCC cells to TKIs.
Yang C; Jin X; Liu X; Wu G; Yang W; Pang B; Jiang J; Liao D; Zhang Y
Cell Death Dis; 2023 Jan; 14(1):47. PubMed ID: 36670097
[TBL] [Abstract] [Full Text] [Related]
3. Hepatitis B virus X protein increases lasp1 SUMOylation to stabilize HER2 and facilitate hepatocarcinogenesis.
You H; Yuan D; Li Q; Zhang N; Kong D; Yu T; Liu X; Liu X; Zhou R; Kong F; Zheng K; Tang R
Int J Biol Macromol; 2023 Jan; 226():996-1009. PubMed ID: 36473530
[TBL] [Abstract] [Full Text] [Related]
4. Hepatitis B virus X protein promotes vimentin expression via LIM and SH3 domain protein 1 to facilitate epithelial-mesenchymal transition and hepatocarcinogenesis.
You H; Yuan D; Bi Y; Zhang N; Li Q; Tu T; Wei X; Lian Q; Yu T; Kong D; Yang X; Liu X; Liu X; Kong F; Zheng K; Tang R
Cell Commun Signal; 2021 Mar; 19(1):33. PubMed ID: 33722250
[TBL] [Abstract] [Full Text] [Related]
5. MicroRNA-326 inhibits cell proliferation and invasion, activating apoptosis in hepatocellular carcinoma by directly targeting LIM and SH3 protein 1.
Hu S; Ran Y; Chen W; Zhang Y; Xu Y
Oncol Rep; 2017 Sep; 38(3):1569-1578. PubMed ID: 28713953
[TBL] [Abstract] [Full Text] [Related]
6. MicroRNA-133b Inhibits Proliferation, Cellular Migration, and Invasion via Targeting lasp1 in Hepatocarcinoma Cells.
Li H; Xiang Z; Liu Y; Xu B; Tang J
Oncol Res; 2017 Sep; 25(8):1269-1282. PubMed ID: 28117027
[TBL] [Abstract] [Full Text] [Related]
7. lasp-1 induces proliferation, metastasis and cell cycle arrest at the G2/M phase in gallbladder cancer by down-regulating S100P via the PI3K/AKT pathway.
Li Z; Chen Y; Wang X; Zhang H; Zhang Y; Gao Y; Weng M; Wang L; Liang H; Li M; Zhang F; Zhao S; Liu S; Cao Y; Shu Y; Bao R; Zhou J; Liu X; Yan Y; Zhen L; Dong Q; Liu Y
Cancer Lett; 2016 Mar; 372(2):239-50. PubMed ID: 26797416
[TBL] [Abstract] [Full Text] [Related]
8. Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
Poynard T; Vergniol J; Ngo Y; Foucher J; Munteanu M; Merrouche W; Colombo M; Thibault V; Schiff E; Brass CA; Albrecht JK; Rudler M; Deckmyn O; Lebray P; Thabut D; Ratziu V; de Ledinghen V; ; ;
J Hepatol; 2014 Apr; 60(4):706-14. PubMed ID: 24291240
[TBL] [Abstract] [Full Text] [Related]
9. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma.
Chua TC; Liauw W; Saxena A; Chu F; Glenn D; Chai A; Morris DL
Liver Int; 2010 Feb; 30(2):166-74. PubMed ID: 19912531
[TBL] [Abstract] [Full Text] [Related]
